Last edition
News about "Harbour BioMed"
Harbour BioMed Secures China IND Approval for HBM7004 in Advanced Solid Tumours
NMPA clearance advances the B7H4xCD3 bispecific antibody toward clinical development, following promising preclinical efficacy and safety results and recent US FDA clearance.
Harbour BioMed | 19/08/2026 | By News Bureau
Harbour BioMed Secures China IND Approval for HBM7004 in Advanced Solid Tumours
NMPA clearance advances the B7H4xCD3 bispecific antibody toward clinical development, following promising preclinical efficacy and safety results and recent US FDA clearance.
Harbour BioMed | 19/08/2026 | By News Bureau
Harbour BioMed and Sinopharm Partner to Advance Research and Development
Harbour BioMed and Sinopharm have partnered to establish an innovation Research and Development (R&D) consortium focused on biologics for oncology and immune-mediated diseases.
Harbour BioMed | 28/07/2026 | By News Bureau
Harbour BioMed Reports Promising Preclinical Data for AI-Driven Drug Candidate LET003
Harbour BioMed announced promising preclinical data for LET003, its first Artificial Intelligence (AI)-enabled drug candidate, highlighting potential as a next-generation obesity therapy targeting ACVR2A/2B.
Harbour BioMed | 18/05/2026 | By News Bureau | 344
Harbour BioMed Secures FDA IND Clearance for HBM7004 in Advanced Solid Tumors
Harbour BioMed receives US Food and Drug Administration (FDA) IND clearance for HBM7004, a novel B7H4xCD3 bispecific antibody developed on its HBICE platform for advanced solid tumors.
Harbour BioMed | 11/05/2026 | By News Bureau
Harbour BioMed Publishes Positive Phase I Data for HBM9378 in Immunology
Harbour BioMed reports favourable safety and pharmacokinetic profile for HBM9378 in Phase I trial, supporting further development for severe immunological disorders.
Harbour BioMed | 23/03/2026 | By News Bureau | 165
National Medical Products Administration approves IND application for HBM7575/SKB575, a long-acting bispecific antibody developed by Harbour BioMed and Kelun-Biotech for treating atopic dermatitis.
Harbour BioMed | 10/03/2026 | By News Bureau | 165
Harbour BioMed has exercised its warrant to acquire shares in Spruce Biosciences, securing a 3.8 percent stake and deepening their collaboration to advance SPR202 for rare endocrine and immune disorders.
Harbour BioMed | 19/01/2026 | By News Bureau | 283
Harbour BioMed Signs Strategic Collaboration with Lannacheng on Radionuclide Drug Conjugates
Harbour BioMed has entered into a long-term strategic collaboration with Yantai Lannacheng Biotechnology to jointly advance the development of next-generation radionuclide drug conjugates, combining both companies’ resources and expertise to accelerate innovation in targeted radiopharmaceutical therapies.
Harbour BioMed | 30/12/2025 | By News Bureau | 168
Harbour BioMed Advances Global Biotherapeutics Collaboration With AstraZeneca
The alliance focuses on discovering and developing next-generation biotherapeutics, including antibody-drug conjugates and T-cell engagers, by combining the scientific strengths of both companies.
Harbour BioMed | 25/11/2025 | By Darshana | 211
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy